
Listing of claims

1. Use of a compound in the manufacture of a medicament for the treatment of a solid tumor in a subject,

the medicament comprising a compound having the formula:




;

or a pharmaceutically acceptable salt thereof; and

a second agent selected from a topoisomerase inhibitor, a DNA alkylating agent, and an androgen receptor signaling inhibitor.

2. Use of a compound in the manufacture of a medicament for the treatment of a solid tumor in a subject,

the medicament comprising a compound having the formula:




; and

a second agent selected from a topoisomerase inhibitor, a DNA alkylating agent, and an androgen receptor signaling inhibitor.

3. Use of a compound in the manufacture of a medicament for administration with a second agent to treat a solid tumor in a subject,

the compound having the formula:




;

or a pharmaceutically acceptable salt thereof; and

wherein the second agent is selected from a topoisomerase inhibitor, a DNA alkylating agent, and an androgen receptor signaling inhibitor.

4. Use of a compound in the manufacture of a medicament for administration with a second agent to treat a solid tumor in a subject,

the compound having the formula:



; and

wherein the second agent is selected from a topoisomerase inhibitor, a DNA alkylating agent, and an androgen receptor signaling inhibitor.

5. The use of Claim 3 or 4, wherein the medicament is formulated for concurrent administration with the second agent.

6. The use of Claim 3 or 4, wherein the medicament is formulated for sequential administration with the second agent.

7. The use of any one of Claims 1 to 6, wherein the second agent is an androgen receptor signaling inhibitor.

8. The use of any one of Claims 1 to 7, wherein the second agent is an androgen receptor signaling inhibitor selected from bicalutamide, enzalutamide, apalutamide, flutamide, nilutamide, darolutamide, and abiraterone acetate.

9. The use of any one of Claims 1 to 8, wherein the second agent is enzalutamide.

10. The use of any one of Claims 1 to 8, wherein the second agent is darolutamide.

11. The use of any one of Claims 1 to 8, wherein the second agent is abiraterone acetate.

12. The use of any one of Claims 1 to 6, wherein the second agent is a DNA alkylating agent.

13. The use of any one of Claims 1 to 6 or 12, wherein the DNA alkylating agent is selected from busulfan, cyclophosphamide, bendmustine, carboplatin, chlorambucil, cyclophosphamide, cisplatin, temozolomide, melphalan, carmustine, lomustine, dacarbazine, oxaliplatin, ifosamide, thiotepa, trabectedin, altretamine, mechlorethamine, procarbazine, and streptozocin.

14. The use of any one of Claims 1 to 6 or 12, wherein the DNA alkylating agent is cisplatin.

15. The use of any one of Claims 1 to 6, wherein the second agent is a topoisomerase inhibitor.

16. The use of any one of Claims 1 to 6 or 15, wherein the topoisomerase inhibitor is a topoisomerase I inhibitor.

17. The use of any one of Claims 1 to 6 or 15, wherein the topoisomerase inhibitor is selected from irinotecan, topotecan, camptothecin, lamellarin, etoposide, teniposide, doxorubicin, daunorubicin, mitoxantrone, amsacrine, ellipticines, aurintricarboxylic acid, HU-331, epirubicin, valrubicin, idarubicin, pixantrone, teniposide, belotecan, gimatecan, indotecan, indimitecan.

18. The use of any one of Claims 1 to 6 and 15 to 17, wherein the topoisomerase inhibitor is irinotecan.

19. The use of any one of Claims 1 to 18, wherein the solid tumor is selected from prostate cancer, small cell lung cancer (SCLC), gastric or gastroesophageal junction (GEJ) adenocarcinoma, and serous ovarian cancer.

20. The use of any one of Claims 1 to 19, wherein the solid tumor is selected from small cell lung cancer (SCLC), gastric or gastroesophageal junction (GEJ) adenocarcinoma, and serous ovarian cancer.


21. The use of any one of Claims 1 to 19, wherein the solid tumor is prostate cancer.

22. The use of claim 21, wherein the prostate cancer is metastatic castration resistant prostate cancer.

23. The use of any one of Claims 1 to 22, wherein the solid tumor is characterized as an advanced tumor.

24. The use of any one of Claims 1 to 23, wherein the solid tumor is characterized as a relapsed solid tumor.


25. The use of any one of Claims 1, 3, and 5 to 24, wherein the compound is of the formula



;

or a pharmaceutically acceptable salt thereof.

26. The use of any one of Claims 2 and 4 to 24, wherein the compound is of the formula



.

27. Use of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide; or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of an advanced relapsed solid tumor.

28. The use of Claim 27, wherein the advanced relapsed solid tumor is advanced relapsed urothelial carcinoma, advanced relapsed ovarian clear cell carcinoma, or advanced relapsed endometrial carcinoma.

29. The use of Claim 27 or 28, wherein the 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide is (2R)-7-chloro-2-(trans-4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide.